Aptamer Sciences Inc

Equities

A291650

KR7291650000

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 03:30:00 10/05/2024 am IST			5-day change	1st Jan Change
2,770 ^KRW	-1.95%		-2.29%	-23.16%

26/03	Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201	CI
2022	Aptamer Sciences Inc announced that it has received KRW 16.5 billion in funding from a group of investors	CI

Aptamer Sciences Inc. has withdrawn its IPO in the amount of KRW 23.4 billion.

March 26, 2020 at 09:30 am IST

Aptamer Sciences Inc. has withdrawn its IPO in the amount of KRW 23.4 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 1,300,000 PriceRange: KRW 18000 Discount Per Security: KRW 720

Latest news about Aptamer Sciences Inc

Aptamer Sciences Inc. Files IND Application for Innovative Liver Cancer Treatment AST-201	26/03	CI
Aptamer Sciences Inc announced that it has received KRW 16.5 billion in funding from a group of investors	06/22/06	CI
Aptamer Sciences Inc announced that it expects to receive KRW 16.5 billion in funding from a group of investors	04/22/04	CI
Aptamer Sciences Inc(KOSDAQ:A291650) dropped from S&P Global BMI Index	19/22/19	CI
Aptamer Sciences Inc.(KOSDAQ:A291650) added to S&P Global BMI Index	22/21/22	CI
Aptamer Sciences Inc. has completed an IPO in the amount of KRW 32.5 billion.	11/20/11	CI
Aptamer Sciences Inc. has filed an IPO.	25/20/25	CI
Aptamer Sciences Inc. has withdrawn its IPO in the amount of KRW 23.4 billion.	26/20/26	CI
Aptamer Sciences Inc. has filed an IPO.	11/19/11	CI
Aptamer Sciences, Inc. announced that it expects to receive $7.3 million in funding	21/16/21	CI

Chart Aptamer Sciences Inc

Duration

Period

More charts

Company Profile

Aptamer Sciences Inc is a Korea-based company principally engaged in the research and development of bio therapeutic drugs. The Company provides services include aptamer synthesis and aptamer discovery. The Company also develops biopharmaceuticals such as insulin substitutes, insulin sensitizers, and liver cancer drugs. In addition, the Company also produces lung cancer diagnostic kits.

Sector

Biotechnology & Medical Research

Calendar

13/05/2024 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APTAMER SCIENCES INC	-23.16%	34.34M
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+48.77%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research